In the last few months, three new vaccines have received approval from the FDA: meningococcal B [Trumenba (Pfizer) and Bexsero (Novartis)] and HPV [Gardasil 9 (Merck)]. The ACIP met in late February to discuss these vaccines and their recommendations to the CDC for potential incorporation into the current immunization schedule. Here is a summary of the committee’s recommendations.